The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adaptation of chemotherapy to the decline tumor markers in patients with poor prognosis nonseminomatous germ cell tumors:Real-world French experience.
 
Marion Rolland
No Relationships to Disclose
 
Sara Faouzi
No Relationships to Disclose
 
Leonor Chaltiel
No Relationships to Disclose
 
Clement Dumont
Travel, Accommodations, Expenses - Ipsen; MSD; Pfizer
 
Lionnel Geoffrois
No Relationships to Disclose
 
Marine Gross-Goupil
Consulting or Advisory Role - amgen; Amgen; Astellas Medivation; AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; ipsen; Janssen-Cilag; MSD Oncology; Pfizer; Roche; Sanofi
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); ipsen (Inst); Janssen-Cilag (Inst); Merck (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; AstraZeneca; ipsen; ipsen; Janssen-Cilag; pfizer; Roche
 
Brigitte Laguerre
No Relationships to Disclose
 
Mathilde Guerin
No Relationships to Disclose
 
Ludovic Doucet
No Relationships to Disclose
 
Guilhem Roubaud
No Relationships to Disclose
 
Magalie Tardy
No Relationships to Disclose
 
Stephane Oudard
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD Oncology; MSD Oncology; Novartis; Pfizer; Roche; Roche; Sanofi
Research Funding - Ipsen; Sanofi
Travel, Accommodations, Expenses - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Merck; MSD Oncology; Novartis; Pfizer; Roche
 
Aude Flechon
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; MSD Oncology; PFIZER; Roche/Genentech; Sanofi/Aventis
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; IPSEN; Janssen-Cilag; MSD Oncology; Pfizer; Roche/Genentech; Sanofi/Aventis
 
Diego Tosi
Consulting or Advisory Role - Actelion (I); Biomarin (I)
Research Funding - Astellas Pharma; Ipsen; Janssen
Patents, Royalties, Other Intellectual Property - I have a pending patent on a new drug combination for prostate cancer treatment
Travel, Accommodations, Expenses - Amicus Therapeutics (I); Astellas Pharma; AstraZeneca; Biomarin (I); MSD; Nutricia (I)
 
Hakim Mahammedi
No Relationships to Disclose
 
Christine Chevreau
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Novartis; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Pfizer/Ipsen
 
Damien Pouessel
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Merck
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Janssen Oncology; Pfizer; Sanofi
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck Sharp & Dohme (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen Oncology; Pfizer
 
Karim Fizazi
Honoraria - Astellas Pharma; Bayer; Janssen; Sanofi
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma; AstraZeneca (Inst); Bayer; Curevac; ESSA (Inst); Janssen Oncology (Inst); Orion; Sanofi (Inst)
Travel, Accommodations, Expenses - Janssen; MSD